Table 1.
Baseline Characteristics and In-Hospital Outcomes of Patients Admitted with COVID-19 With and Without Convalescent Plasma Therapy
| All hospitalizations | Propensity-matched hospitalizations | |||||
|---|---|---|---|---|---|---|
| Without convalescent plasma (n = 8452) | With convalescent plasma (n = 1113) | p value | Without convalescent plasma (n = 960) | With convalescent plasma (n = 960) | p value | |
| Age, (mean, SD), year | 65.0 (17.1) | 64.8 (16.1) | 0.80 | 64.9 (16.1) | 64.5 (16.2) | 0.57 |
| Male, n (%) | 4568 (54.0) | 667 (59.9) | <0.001 | 584 (60.8) | 576 (60.0) | 0.74 |
| Asthma, n (%) | 499 (5.9) | 44 (4.0) | 0.01 | 42 (4.4) | 40 (4.2) | 0.91 |
| COPD, n (%) | 369 (4.4) | 57 (5.1) | 0.28 | 49 (5.1) | 46 (4.8) | 0.83 |
| Hypertension, n (%) | 3094 (36.6) | 381 (34.2) | 0.13 | 329 (34.3) | 337 (35.1) | 0.74 |
| Diabetes mellitus, n (%) | 2017 (23.9) | 228 (20.5) | 0.014 | 191 (19.9) | 200 (20.8) | 0.65 |
| Chronic kidney disease, n (%) | 1017 (12.0) | 127 (11.4) | 0.58 | 114 (11.9) | 115 (12.0) | 1.00 |
| Cancer, n (%) | 734 (8.7) | 130 (11.7) | 0.001 | 107 (11.1) | 110 (11.5) | 0.89 |
| Heart failure, n (%) | 777 (9.2) | 83 (7.5) | 0.065 | 75 (7.8) | 67 (7.0) | 0.54 |
| Oxygen saturation, (median [IQR]) | 90.0 [84.0, 93.0] | 88.0 [79.0, 91.0] | <0.001 | 88.0 [79.0, 91.0] | 88.0 [79.8, 91.0] | 0.74 |
| Respiratory rate, (median [IQR]) | 19.0 [18.0, 21.0] | 20.0 [18.0, 22.0] | <0.001 | 20.0 [18.0, 23.0] | 20.0 [18.0, 22.0] | 0.26 |
| D-dimer, μg/mL (median [IQR]) | 1.42 [0.78, 2.70] | 1.06 [0.64, 1.94] | <0.001 | 1.21 [0.70, 2.02] | 1.06 [0.64, 1.90] | 0.004 |
| C reactive protein, mg/L (median [IQR]) | 88.1 [37.1, 167.1] | 85.8 [43.9, 161.6] | 0.47 | 92.5 [45.7, 157.1] | 84.3 [42.7, 159.6] | 0.50 |
| Therapeutic anticoagulation during hospitalization, n (%) | 2604 (30.8) | 525 (47.2) | <0.001 | 436 (45.4) | 426 (44.4) | 0.68 |
| Steroid during hospitalization, n (%) | 3802 (45.0) | 949 (85.3) | <0.001 | 810 (84.4) | 817 (85.1) | 0.70 |
| Use of remdesivir | 1066 (12.6) | 530 (47.6) | <0.001 | 438 (45.6) | 448 (46.7) | 0.68 |
| Use of IL-6 inhibitor | 274 (3.2) | 50 (4.5) | 0.038 | 45 (4.7) | 42 (4.4) | 0.83 |
| ICU admission | 1592 (18.8) | 332 (29.8) | <0.001 | 282 (29.4) | 270 (28.1) | 0.58 |
| Endotracheal intubation, n (%) | 1052 (12.4) | 214 (19.2) | <0.001 | 182 (19.0) | 177 (18.4) | 0.82 |
| In-hospital death, n (%) | 1961 (23.2) | 279 (25.1) | 0.18 | 250 (26.0) | 241 (25.1) | 0.68 |
| Acute kidney injury, n (%) | 2313 (27.8) | 319 (28.7) | 0.56 | 273 (28.4) | 261 (27.2) | 0.58 |
COPD chronic obstructive pulmonary disease, ICU intensive care unit, IL-6 interleukin-6, SD standard deviation